The rationale of this study is to evaluate the impact of renal function on the PK, safety, and tolerability of VIR-2218 in participants with normal renal function and participants with varying degrees of renal dysfunction who are otherwise medically stable

Participants may be enrolled in Cohorts 1 and 2 in a non-randomized way.

Inclusion Criteria for All Participants:

• Participants must have stable renal function as defined by less than 20% change in estimated glomerular filtration rate (eGFR) between the first and second screening sample with the first screening visit occurring within 28 days prior to dosing on Day 1 and the second screening visit occurring no more than 14 days apart, but at least 72 hours apart from the first.
• Body mass index (BMI) within the range 18.5 to 40.0 kg/m^2 at screening.
• Female and Male participants must consent to follow contraception requirements
• Capability of giving signed informed consent form

Inclusion Criteria: Additional Criteria Specific to Healthy Participants:

• Must be in the opinion of the investigator, be in good health based upon medical history, vital signs, physical examination, and screening laboratory evaluations
• Must have normal renal function as defined by eGFR ≥ 90 mL/min/1.73m^2 based on the Modification of Diet in Renal Disease (MDRD) equation determined from the mean of two measurements of serum creatinine at screening.

Inclusion Criteria: Additional Criteria Specific to Participants with Renal Impairment

• Participants must, in the opinion of the investigator, be sufficiently healthy for study participation based on medical history, physical examination, vital signs, and screening laboratory evaluations
• Participants with RI must have chronic moderate or severe RI and be clinically stable per investigator assessment for at least 3 months prior to screening
• Moderate RI as defined by eGFR level 30-59 mL/min/1.73m^2 based on the MDRD equation, or
• Severe RI as defined by eGFR level 15-29mL/min/1.73m^2 based on the MDRD equation

Exclusion Criteria: Criteria for All Participants

• Any clinically significant medical condition or psychiatric condition that may interfere with study intervention
• Participants with uncontrolled hypertension, asthma, and/or diabetes (Type I or II).
• Participants with diabetes
• Participants with any active malignancy
• Participants with vasculitis or conditions associated with vasculitis.
• Participants who have undergone major surgery within 12 months of screening
• Participants with unstable cardiac functions, abnormality, or clinically significant heart failure
• Participants with infection of HIV, HAV, HBV, HCV, HDV, or HEV
• Participants with signs of active infection
• History of bone marrow or solid organ transplantation
• Participants with end-stage renal disease or nephrotic syndrome as defined by: participants requiring hemodialysis or peritoneal dialysis, participants who have undergone or are listed for transplant, or participants who have chronic kidney disease with nephrotic syndrome
• Participants with active nephritis
• Participants with clinically significant liver disease
• History of drug or alcohol abuse
• Unwillingness or inability to follow procedures outlined in protocol

Exclusion Criteria: Additional Criteria Specific to Healthy Participants

• Use of any prescription medications or over-the-counter medications (with the exception of vitamins and/or hormonal contraceptive medications) including herbal products within 30 days prior to D1 of study participation

Exclusion Criteria: Additional Criteria Specific to Participants with Renal Impairment

• Not on stable dose and regimen of any medication(s) (prescription or over-the-counter) that the participants is taking regularly (eg, medications for chronic conditions such as hypertension, high cholesterol, or depression must not be changed in dose or type for at least 2 weeks prior to study drug administration). Use of other prescription medications or over-the-counter medications that are not for chronic conditions (with the exception of vitamins and/or hormonal contraceptive medications) including herbal products within 30 days prior to D1 of study participation